

Odette S Reifsnider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7522827/publications.pdf>

Version: 2024-02-01

6
papers

79
citations

1478280

6
h-index

1872570

6
g-index

6
all docs

6
docs citations

6
times ranked

72
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC Heart Failure, 2020, 7, 3910-3918.	1.4	17
2	Cost-effectiveness analysis of empagliflozin versus sitagliptin as <scp>secondâ€line</scp> therapy for treatment in patients with type 2 diabetes in the United States. Diabetes, Obesity and Metabolism, 2021, 23, 791-799.	2.2	17
3	Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Research and Care, 2021, 9, e001313.	1.2	15
4	Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases, 2022, 79, 796-806.	2.1	14
5	<scp>Costâ€effectiveness</scp> of <scp>secondâ€line</scp> empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes, Obesity and Metabolism, 2022, 24, 652-661.	2.2	9
6	Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. Farmeconomia E Percorsi Terapeutici, 2017, 18, .	0.2	7